You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
The company is selling 4,166,666 shares of its common stock at a price of $60 per share in the offering, which is expected to close Sept. 15.
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.
The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.
The LUNGevity Foundation and 41 stakeholders aim to reduce cancer patients' confusion about in vitro diagnostic testing by implementing two consistent umbrella terms.
Thermo Fisher has also applied to the Japanese Ministry of Health, Labor, and Welfare to expand the use of the Oncomine Dx Target test in Japan.
Genetron's S5 sequencer is based on Thermo Fisher's Ion GeneStudio S5 instrument and is cleared for clinical use by China's NMPA.
The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.